GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oramed Pharmaceuticals ORMP · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.00

+3.63%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$2.0m

FY2016FY2025

Net income

$64.0m

FY2016FY2025

Free cash flow

−$11.1m

FY2016FY2025

Shareholders' equity

$199.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$2.0m—$1.3m$2.7m$2.7m$2.7m$2.7m$2.4m$2.5m$641,000
Research and development$6.4m$6.3m$9.0m$27.6m$21.0m$10.2m$13.5m$12.0m$10.3m$7.7m
Operating income−$15.1m−$12.8m−$15.8m−$40.6m−$24.2m−$11.8m−$14.6m−$13.5m−$10.8m−$10.0m
Net income$64.0m−$19.1m$5.5m−$37.8m−$22.2m−$11.5m−$14.4m−$12.7m−$10.5m−$11.0m
Diluted earnings per share1.58-0.480.14-0.97-0.61-0.48-0.82-0.73-0.74-0.83

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$230.9m$155.3m$220.6m$161.6m$128.0m$44.6m$34.7m$47.4m$38.7m$42.8m
Cash and short-term investments$125.9m$141.9m$162.0m$155.7m$94.1m$39.9m$32.3m$30.5m$20.1m$31.0m
Total liabilities$31.1m$9.9m$57.7m$10.5m$11.5m$11.8m$15.3m$16.3m$19.5m$16.6m
Debt$285,000—$51.0m——$44,000————
Shareholders' equity$199.7m$146.3m$163.8m$151.8m$115.8m$32.9m$19.4m$31.1m$19.2m$26.2m
Shares outstanding40m40m40m39m37m24m17m17m14m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$9.1m−$8.4m−$10.3m−$28.7m−$21.2m−$12.4m−$12.9m−$14.7m−$5.8m$4.7m
Capital spending−$1.9m−$17,999−$253,999−$495,999−$374,999−$81,999−$14,999−$4,999−$6,999−$9,000
Free cash flow−$11.1m−$8.4m−$10.5m−$29.2m−$21.6m−$12.5m−$13.0m−$14.7m−$5.8m$4.6m
Dividends paid−$10.9m—————————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—————$2.0m——
Operating income−$2.8m−$3.7m−$5.7m−$2.4m−$2.5m−$4.5m−$3.6m−$3.1m
Net income$78.2m$38.3m$10.0m$48.4m$13.3m−$7.6m−$10.2m−$19.6m
Diluted earnings per share1.840.900.251.200.33-0.19-0.26-0.49
Cash from operations—−$2.0m—−$1.0m−$3.0m−$3.0m−$1.0m−$7.0m
Total assets$369.6m$268.8m$230.9m$220.5m$161.7m$147.5m$155.3m$165.1m
Cash and short-term investments$50.6m$65.8m$125.9m$134.7m$97.9m$130.6m$141.9m$142.3m
Debt$249,000$268,000$285,000$271,000$264,000$181,000$216,000$243,000
Shareholders' equity$317.5m$238.3m$199.7m$203.3m$154.5m$140.8m$146.3m$156.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-9.6%-5.9%—
Operating income-28.1%5.1%7.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings1.8-5.116.9-2.9-5.5-2.1-1.5-1.0-2.9-1.7
Price to sales57.6—69.640.945.68.87.85.012.329.7

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return24%7%20%-47%244%-17%42%-56%39%-28%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 16 Jan 2026.

FY2026
Paid in the year0.25
  • 12-to-1 reverse split · 23 Jan 2013
  • 3.3-for-1 split · 14 Jun 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.